DNA damage response (DDR) inhibitors, such as poly (ADP-ribose) polymerase (PARP) inhibitors, are a type of targeted therapy used to treat cancers with existing defects in DNA repair, such as BRCA mutant cancers.
DDR inhibitors block critical DNA repair pathways that these cancers rely on to repair their DNA as they grow and divide. Other important DDR players being targeted by researchers are ataxia telangiectasia and Rad3-related...
Triple-negative breast cancer (TNBC) makes up 15 to 20 percent of breast cancer diagnoses. The condition often is considered a single disease...
Over the past decade, immune checkpoint inhibitors have shown success in treating several types of cancer, including melanoma, non-small cell...